Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851
Shots:
- Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indications
- As per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete agreed upon IND-enabling activities, after which Novo will file for IND & lead further development
- In preclinical studies, LX9851 + semaglutide showed a reduction in weight, food intake & fat mass, plus mitigated weight regain & improved liver steatosis post-semaglutide discontinuation; data was presented at the Obesity Week 2024
Ref: Lexicon | Image: Lexicon & Novo Nordisk
Related News:- Viatris Join Forces with Lexicon Pharmaceuticals to Commercialize Sotagliflozin Across all Markets Outside of the US and EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
